The novel coronavirus, SARS-CoV-2, or 2019-nCoV, which originated in Wuhan, Hubei province, China in December 2019, is a grave threat to public health worldwide. A total of 3,672,238 confirmed cases of coronavirus disease 2019 (COVID-19) and 254,045 deaths were reported globally up to May 7, 2020. However, approved antiviral agents for the treatment of patients with COVID-19 remain unavailable. Drug repurposing of approved antivirals against other viruses such as HIV or Ebola virus is one of the most practical strategies to develop effective antiviral agents against SARS-CoV-2. A combination of repurposed drugs can improve the efficacy of treatment, and structure-based drug design can be employed to specifically target SARS-CoV-2. This review discusses therapeutic strategies using promising antiviral agents against SARS-CoV-2. In addition, structural characterization of potentially therapeutic viral or host cellular targets associated with COVID-19 have been discussed to refine structure-based drug design strategies.
【저자키워드】 COVID-19, SARS-CoV-2, 2019-nCoV, Antiviral agents, Therapeutic strategies, crystal structure, 【초록키워드】 Treatment, coronavirus disease, Drug repurposing, public health, HIV, Efficacy, Antiviral, drug design, virus, Novel coronavirus, Repurposed drug, China, Wuhan, therapeutic, death, target, antiviral agent, therapeutic strategy, Ebola virus, cellular, Combination, confirmed case, Host, effective, IMPROVE, develop, reported, addition, approved, patients with COVID-19, with COVID-19, 【제목키워드】 review, Strategy, characterization, Against,